Lilly and Novo Nordisk name GLP-1 and amylin drugs getting data at EASD 2026

Eli Lilly and Novo Nordisk have each said which programs will produce new data at the European Association for the Study of Diabetes (EASD) 2026 meeting, naming specific molecules ahead of the conference, which runs September 28 to October 2 in Milan, Italy ^[1][2][3].

Lilly said on September 15 that it will present data on Foundayo (orforglipron), retatrutide and eloraTZP ^[1][2]. Foundayo is an FDA-approved once-daily oral GLP-1 receptor agonist for adults with obesity, or some adults with overweight who also have weight-related medical problems, and it is being studied for type 2 diabetes and other conditions ^[1][2]. Retatrutide is an investigational once-weekly triple hormone receptor agonist that acts on GIP, GLP-1 and glucagon, and is legally available only to participants in Lilly's trials ^[1][2]. EloraTZP is an investigational combination of eloralintide, a selective amylin receptor agonist, and tirzepatide, the molecule in Mounjaro and Zepbound ^[1][2].

Lilly's announcement lists results from the trials being presented. In the Phase 3 TRIUMPH-2 trial of retatrutide, adults with obesity or overweight and type 2 diabetes lost up to an average of 49.6 pounds (22.5 kg, or 20.8%) and lowered A1C by up to an average of 1.6 percentage points at 80 weeks ^[1][2]. In ACHIEVE-4, described as the largest and longest study of Foundayo in type 2 diabetes, the drug was non-inferior to insulin glargine, with a 16% lower risk of MACE-4 events (HR 0.84; 95.0% CI 0.59 to 1.20) and a 23% lower risk of MACE-3 events (HR 0.77; 95.0% CI 0.52 to 1.13) in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk ^[1][2]. A Phase 1 eloraTZP study found that adding eloralintide 3 mg to tirzepatide 5 mg led to 17% weight loss over 16 weeks, versus 10% with tirzepatide 5 mg alone ^[1][2].

Lilly's scheduled sessions include a retatrutide symposium on Wednesday, September 30, at 8:30 a.m. CEST, an eloraTZP Phase 2 symposium that day at 4:30 p.m. CEST, and a Foundayo symposium on Thursday, October 1, at 8:30 a.m. CEST ^[1][2]. The company will also hold an industry symposium on Monday, September 28, from 10 a.m. to 4 p.m. CEST ^[1][2].

Novo Nordisk said on September 16 that it will present 44 abstracts covering semaglutide, CagriSema and zenagamtide ^[3]. Semaglutide is the molecule in Ozempic, Wegovy and Rybelsus. CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analog, and semaglutide, studied in the REDEFINE and REIMAGINE programs ^[3]. Zenagamtide, formerly known as amycretin, is a single-molecule GLP-1 and amylin receptor agonist being tested in the AMAZE and AMBITION programs ^[3].

Novo's list includes real-world results from the OCTANE study on three-month weight outcomes in adults with overweight or obesity who switched from injectable semaglutide or tirzepatide to oral semaglutide, and COMPETE SWITCH CV, which looks at major adverse cardiovascular events in adults with type 2 diabetes who escalated to semaglutide 2.0 mg compared with those who switched to tirzepatide ^[3]. Other presentations cover CagriSema's effects on appetite, eating behavior and brain responses to food cues measured by fMRI, CagriSema and bone remodeling, semaglutide's effect on liver measures, and Phase 2b results for zenagamtide in type 2 diabetes ^[3]. Novo's release did not include efficacy figures for these new analyses, and the company noted that accepted abstracts include preliminary data that may change in final published manuscripts ^[3].

Why it matters for patients

Most of the molecules in these announcements are not approved for any use. Retatrutide, eloraTZP, CagriSema and zenagamtide are all investigational, meaning they are available only to people enrolled in clinical trials ^[1][2][3]. Nothing in either announcement changes what is currently prescribed or covered.

Several of the planned analyses speak to questions patients already raise. The OCTANE real-world data concern people who moved from injectable semaglutide or tirzepatide to oral semaglutide for weight management, a switch some patients consider for convenience ^[3]. COMPETE SWITCH CV compares cardiovascular events in people with type 2 diabetes who increased their semaglutide dose to 2.0 mg against those who changed to tirzepatide, a choice clinicians and patients face when a current treatment is not meeting goals ^[3]. The Foundayo and retatrutide results address oral and triple-agonist options that do not yet have approval for type 2 diabetes ^[1][2].

Conference abstracts are summaries. Full results, peer review and any regulatory review are separate steps, and none of those steps have been disclosed for these datasets.

What happens next

EASD 2026 runs September 28 to October 2 in Milan ^[1][2][3]. Lilly's industry symposium is September 28; its retatrutide and Mounjaro symposia are September 30 at 8:30 a.m. CEST, followed by the eloraTZP symposium at 4:30 p.m. CEST, and the Foundayo symposium is October 1 at 8:30 a.m. CEST ^[1][2]. Novo Nordisk will hold an international press briefing, available by webcast, on Wednesday, September 30 ^[3]. Novo has not disclosed whether it will seek new approvals based on any of the data being presented ^[3].